Skip to main content

Table 6 Recent updates on CAR-T cell therapy for multiple myeloma

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

  Ide-Cel (bb2121) (KarMMA) bb21217 (CRB-402) Cilta-Cel (CARTITUDE-1) CT053 (LUMMICAR-2) Orva-Cel (EVOLVE) FasT (GC012F) P-BCMA-101 (PRIME) Universal
ALLO-715
Phase 2 1 1b/2 1b/2 1/2 1 1/2 1
Patients (n) 128 46 97 14 44 16 43 15
Target BCMA BCMA with PI3Ki bb007 2-epitope BCMA BCMA BCMA Dual BCMA-CD19 BCMA BCMA
ORR/CR/MRD 73%/33%/26% 55%/18%/NA 95%/56%(sCR)/94.2% 100%/29%/92% 91%/39%/84% 93.8%/NA/56.3% 57%/NA/NA 33%/NA/NA
Median PFS (month) 8.8mo NA Not reached NA NA NA NA NA
Median OS (month) 19.4mo NA Not reached NA NA NA NA NA
CRS, any grade 84% 67% 94.8% 86% NA 87.5% 17% 24%
CRS, >  = grade3 5% 4% (one grade 5) 4.1% 0% 2% 12.5% 2% 0%
Neurotoxicity, any grade 18% 22% 20.6% 7% NA 0% 2% 0%
Neurotoxicity, >  = grade3 3% 7% 10.3% 0% 4% 0% 0% 0%
Reference [54]
NEJM 2021
[57]
ASH 2020 #653
[55]
ASH 2020 #177
[56]
ASH 2020 #133
[58]
ASCO 2020 #8504
[61]
ASH 2020 #178
[59]
ASH 2020 #134
[62]
ASH 2020 #129
  1. NA, not available; ORR, overall response rate; CR, complete response; MRD, minimal residual disease; PFS, progression-free survival; OS, overall survival; CRS, cytokine release syndrome